Loading...
Market
Which company will commercialize the new lupus treatment by December 31, 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Press releases or official announcements from the companies
Story
Discovery of Immune Defect by Chicago Researchers Could Lead to Lupus Cure
Jul 11, 2024, 01:00 AM
Researchers have identified a molecular defect in the immune system that may be the root cause of lupus, a life-threatening condition. This discovery, described as a 'molecular switch' or 'naturally occurring seesaw,' could potentially reverse the harmful immune response and lead to new treatments or a cure for the autoimmune disorder. The breakthrough was made by scientists from Northwestern Medicine, Brigham and Women's Hospital, and Chicago researchers, pointing to a future where the immune cells driving lupus damage could be turned into beneficial cells, thereby saving tissue and preventing the immune system from attacking the body.
View original story
Similar markets
Yes • 50%
No • 50%
Major acquisition by competitor • 25%
New drug development announced • 25%
Price reduction of existing drugs • 25%
No significant response • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%